Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients

Head and neck squamous cell carcinoma (HNSCC) patients treated with high-dose cisplatin concurrently with radiotherapy (hdCis-RT) commonly suffer kidney injury leading to acute and chronic kidney disease (AKD and CKD, respectively). We conducted a retrospective analysis of renal function and kidney...

Descripción completa

Detalles Bibliográficos
Autores principales: Mapuskar, K.A., Vasquez Martinez, G., Pulliam, C.F., Petronek, M.S., Steinbach, E.J., Monga, V., Furqan, M., Jetton, J.G., Saunders, D.P., Pearce, A., Davidson, S., Pitre, L., Dunlap, N.E., Fairbanks, R., Lee, C.M., Mott, S.L., Bodeker, K.L., Cl, Huang, Buatti, J.M., Anderson, C.M., Beardsley, R.A., Holmlund, J.T., Zepeda-Orozco, D., Spitz, D.R., Allen, B.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852651/
https://www.ncbi.nlm.nih.gov/pubmed/36640725
http://dx.doi.org/10.1016/j.redox.2022.102599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852651/
https://www.ncbi.nlm.nih.gov/pubmed/36640725
http://dx.doi.org/10.1016/j.redox.2022.102599

Ejemplares similares